[379] GAMIDA CELL

Julian Adams[1], [1] Gamida Cell
ABSTRACT TEMPLATE for Company Presentations

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

- **Investment Rational**
  Each year, 70,000 patients worldwide are in need of a donor-derived stem cell transplant, but nearly 40% never make it to transplant. Gamida Cell's world-class scientists and leadership team, with deep expertise in stem cell therapy and drug development, are harnessing a novel cell expansion technology to deliver potentially curative treatments for patients with blood cancers and rare genetic diseases.

- **Core Technology**
  Gamida Cell's innovative approach in cellular therapy is based on the company's proprietary NAM technology, which addresses limitations in cell expansion by increasing the number of cells in culture to create potentially life-saving therapies. NAM technology is being applied to multiple therapeutic programs, including a bone marrow transplant alternative and immunotherapy, for patients with blood cancers and rare genetic diseases.

- **Business Strategy**
  Leveraging NAM technology, Gamida Cell is advancing lead phase III clinical program, NiCord, as a universal bone marrow transplant solution. NiCord has been associated with improved clinical outcomes and reduced morbidity, which can lead to shorter hospital stays and reduced resource utilization. Gamida Cell is also focused on expanding in-house manufacturing capabilities to produce NAM technology-based therapies.

- **Product Profile/Pipeline**
  Using NAM technology, Gamida Cell is building a diverse pipeline targeting cancers and rare genetic diseases. Lead investigational therapy, NiCord, is in phase III development to treat high-risk hematologic malignancies. NiCord is also being investigated for rare genetic diseases, including aplastic anemia. Early-stage candidate NAM-NK cells is an immunotherapy designed for patients with blood cancer and solid tumors.

- **What's Next?**
  Gamida Cell is continuing to support the phase III NiCord study, with plans to increase the number of trial sites, anticipating enrollment completion in the second half of 2019. The company will continue to advance early and mid-phase pipeline programs, as well as build the US-based leadership team and invest in in-house manufacturing capabilities in preparation for potential commercialization.